NeoRelapse · Neoadjuvant Ipilimumab/Nivolumab · Recurrent, High Risk, Resectable Melanoma
Trial status changed: Recruiting → Withdrawn
Also in this update: Primary completion moved earlier from Aug 2027 to Oct 2026; Study completion moved earlier from Aug 2030 to Oct 2026
University of UtahPhase 2 NCT06365619 Registry history of NCT06365619 on ClinicalTrials.gov (opens the registry)